West Pharmaceutical Services said its shareholders approved an amendment and restatement of the 2016 Omnibus Incentive Compensation Plan in this 8-K/A.

1. 01

   West Pharmaceutical Services said its shareholders approved an amendment and restatement of the 2016 Omnibus Incentive Compensation Plan in this 8-K/A.

2. 02

   The company said the shareholder approval was reported in its original Form 8-K filed on May 8, 2025, and the earliest event date reported in this 8-K/A is May 6, 2025.

3. 03

   The company said the material provisions of the amended and restated plan are described in detail in its definitive proxy statement filed on March 21, 2025, and are qualified in their entirety by the full text of the amended plan attached to this 8-K/A.

4. 04

   The company attached the Amended and Restated 2016 Omnibus Incentive Compensation Plan as Exhibit 10.15 to Item 9.01, and Exhibit 104 is the cover page in Inline XBRL format for the 8-K.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.